Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies including molecular reference standards, today announces the launch of its first HDx™ cfDNA (cell-free DNA) Reference Standard in Synthetic Plasma.
Since being pioneered by Horizon co-founder Professor Alberto Bardelli for the detection of KRAS mutations in serum to identify resistant populations to EGFR targeted therapy, liquid biopsy testing has emerged as one of the fastest growing areas in diagnostics, with cfDNA testing set to reach $9.0 billion by 20221. Non-invasive testing offers the possibility of earlier disease detection and more effective treatment, even more so for conditions such as lung cancer which are difficult to biopsy.
cfDNA based diagnostics are at a particularly high risk of error however, as these tests involve extracting a small amount of DNA from a large volume of plasma, and an assay may be required to identify as ...
